Barbara Weber - 02 Feb 2026 Form 4 Insider Report for Tango Therapeutics, Inc. (TNGX)

Role: Director, Executive Chair, Director
Signature: /s/ Daniella Beckman, as attorney-in-fact
Issuer symbol: TNGX
Transactions as of: 02 Feb 2026
Net transactions value: -$374,294
Form type: 4
Filing time: 04 Feb 2026, 20:09:06 UTC
Previous filing: 06 Feb 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Weber Barbara	Director, Executive Chair, Director	C/O TANGO THERAPEUTICS, INC.,, 201 BROOKLINE AVE., SUITE 901, BOSTON	/s/ Daniella Beckman, as attorney-in-fact	04 Feb 2026	0001800670

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TNGX	Common Stock	Award	$0	+37,522	+2.3%	$0.000000	1,659,773	02 Feb 2026	Direct	F1
transaction	TNGX	Common Stock	Sale	$369,999	-30,186	-1.8%	$12.26	1,629,587	03 Feb 2026	Direct	F2, F3
transaction	TNGX	Common Stock	Sale	$4,295	-333	-0.02%	$12.90	1,629,254	03 Feb 2026	Direct	F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TNGX	Stock Option (Right to Buy)	Award	$0	+222,132		$0.000000	222,132	02 Feb 2026	Common Stock	222,132	$11.94	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in full on February 1, 2027, subject to the Reporting Person's continuous service with the Issuer as of such vesting date.
F2	The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
F3	Represents the weighted average sales price per share. The shares sold at prices ranging from $11.88 to $12.875 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F4	Represents the weighted average sales price per share. The shares sold at prices ranging from $12.88 to $12.91 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F5	This option shall vest and become exercisable in 12 equal monthly installments following January 1, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.